author-photo

Roberta Cereda

32

Papers

342

Citations

Citation Trend

Filter By

Papers (24) Sort By

Journal Conference Others

Corrigenda to Phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors [Ann Oncol, 25 (2014) 2244-2251] DOI: 10.1093/annonc/mdu390

2015 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (2)
1032PPROLONGED ANTI-TUMOR ACTIVITY OF LUCITANIB IN ADVANCED THYROID CANCER

2014 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (2)
HPLC-MS/MS method for quantitative determination of the novel dual inhibitor of FGF and VEGF receptors E-3810 in tumor tissues from xenograft mice and human biopsies

2014 Journal of Mass Spectrometry
Show All
- Source
- Cite
- Save
Citations (3)
Phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors

2014 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (127)
A phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors.

2014 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (6)
A single arm, open-label, phase II study to assess the efficacy of lucitanib in patients with FGFR1-amplified squamous NSCLC (sqNSCLC).

2014 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (4)
A first in human phase I study of the proteasome inhibitor CEP-18770 in patients with advanced solid tumours and multiple myeloma

2013 European Journal of Cancer
Show All
- Source
- Cite
- Save
Citations (62)
Development and validation of a high-performance liquid chromatography-tandem mass spectrometry method for the determination of the novel inhibitor of angiogenesis E-3810 in human plasma and its application in a clinical pharmacokinetic study.

2011 Journal of Mass Spectrometry
Show All
- Source
- Cite
- Save
Citations (4)
First-in-man study of E-3810, a novel VEGFR and FGFR inhibitor, in patients with advanced solid tumors.

2011 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (12)
Abstract 1367: The dual selective VEGFR-FGFR kinases inhibitor E-3810 decreases tumor perfusion and inhibits tumor growth: an analysis using dynamic contrast-enhanced magnetic resonance imaging

2010 Cancer Research
Show All
- Source
- Cite
- Save
Citations (2)